At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix with stage IVB, recurrent, or persistent disease
- ✓Disease not amenable to curative surgery and/or radiotherapy
- ✓At least 1 unidimensionally measurable lesion (≥20 mm by conventional imaging or ≥10 mm by spiral CT)
- ✓Target lesion must be outside previously irradiated field
- ✕No prior chemotherapy except when concurrently administered with radiotherapy
- ✕No bilateral hydronephrosis unless alleviated by ureteral stents or percutaneous drainage
- ✕No prior or concurrent malignancy within 5 years except nonmelanoma skin cancer
- ✕No concurrent clinically significant infection
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix
In Brief
A Phase 3 clinical trial evaluating Cisplatin, Gemcitabine Hydrochloride, and 4 other interventions for Cervical Adenocarcinoma and 4 related conditions. Completed, enrolled 513 participants across 1 site.
Detailed Summary
This randomized phase III trial is studying four combination chemotherapy regimens using cisplatin to compare how well they work in treating women with stage IVB, recurrent, or persistent cancer of the cervix. Drugs used in chemotherapy such as cisplatin, paclitaxel, vinorelbine, gemcitabine, and topotecan, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen containing cisplatin is most effective in treating cervical cancer.
Study Details
Timeline
Interventions
Given IV
Given IV
Ancillary studies
Given IV
Given IV